Supplementary Figure 1. Diagram of study selection for literature review of PET vs AP comparisons in R+ orthotopic liver transplant patients.

92 Abstracts Excluded
Reasons for Exclusion:
- Not English language
- Pre-emptive therapy only
- Antiviral prophylaxis only
- Comparison of CMV Detection Methods
- Antivirals comparison
- Non-liver organ transplant
- Pediatrics population

Electronic PubMed Search of
As November 4, 2016
(n=106)

Title & Abstract Screening

Abstracts Potentially Eligible
(n=14)

Full Text Review

Included Studies in Analysis
(n=5)

8 Studies Excluded
Reasons for Exclusion:
- Meta-analysis or review papers (4)
- Acyclovir used as prophylaxis drug (no longer standard of care) (1)
- D+/R- subjects only (3)
- No stratification of outcomes by R+ serostatus

D+, donor seropositive; R+, recipient seropositive; CMV, cytomegalovirus
Supplementary Figure 2. Details of AP and PET cohorts.

OLT Patients
N=493
(OLT between 1/1/09-4/27/15)

110 D+/R- and 57 D-/R-
patients excluded

R+ OLT
Patient
N=326

Historical Cohort
(OLT between 1/1/09-4/27/15)

Antiviral Prophylaxis
N=162

6 patients with multi-organ transplant excluded

Antiviral prophylaxis R+
OLT Recipients
N=156

Prospective Cohort
(OLT between 1/1/09-4/27/15)

Preemptive Therapy
N=164

4 Patients with multi-organ transplant excluded

Preemptive Therapy R+
OLT Recipients
N=160

PET, pre-emptive therapy; AP, antiviral prophylaxis; D+, donor seropositive; R+, recipient seropositive; CMV, cytomegalovirus
Supplementary Figure 3. Kaplan-Meier estimates of CMV disease according to CMV prevention strategy.
Supplementary Figure 4. Kaplan-Meier estimates of acute cellular rejection according to CMV prevention strategy.